2023 financial results and business update
Category: Press release
Transgene Announces Upcoming Investor Meetings
upcoming investor meetings
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
TG4050 AACR 2024
Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Transgene Nec and BostonGene expand collaboration
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
financial calendar 2024
Transgene Announces Financial Calendar for 2024
financial calendar 2024
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Transgene and NEC extend their collaboration
Transgene Announces Upcoming Investor Meetings
upcoming investor meetings
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
nomination A Dubarry
Transgene reports business update and Q3 2023 financial position
Q3 2023 financial position
